日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma

FDA批准摘要:Teclistamab——一种用于治疗复发或难治性多发性骨髓瘤患者的双特异性CD3 T细胞衔接器

Baines, Andrea C; Kanapuru, Bindu; Zhao, Jay; Price, Lauren S L; Zheng, Nan; Konicki, Robyn; Manning, Michael L; Gehrke, Brenda J; Theoret, Marc R; Gormley, Nicole J

FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes

FDA批准摘要:用于治疗骨髓增生异常综合征的地西他滨和西达扎瑞丁片

Kim, Nina; Norsworthy, Kelly J; Subramaniam, Sriram; Chen, Haiyan; Manning, Michael L; Kitabi, Eliford; Earp, Justin; Ehrlich, Lori A; Okusanya, Olanrewaju O; Vallejo, Jonathon; Gehrke, Brenda J; de Claro, R Angelo; Pazdur, Richard

Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.

从人类精液中纯化的市售 PSA 受到胰蛋白酶样蛋白水解酶的污染

Manning Michael L, Kostova Maya, Williams Simon A, Denmeade Samuel R